Immune cells in tumor microenvironment play a prominent role in
tumor progression and
metastasis. MicroRNA-155 (miR-155) represents an important player in innate and adaptive immunity by regulating differentiation, maturation and activation of macrophages, dendritic cells, B cells and T cells. However, the role of miR-155 expression in immune cells in solid
tumor development is less elucidated. Our current study showed that both B16-F10
melanoma and
Lewis lung carcinoma tumors grew much faster in
bic/miR-155 knockout (miR-155(-/-) ) mice along with an increase of myeloid-derived suppressor cells (MDSCs) accumulation in
tumors, compared to that in wild-type mice.
Bone marrow transplantation study showed that bone marrow miR-155 deficiency could replicate the above
tumor-promoting phenotype. In vitro study demonstrated that
tumor-infiltrating miR-155(-/-) MDSCs showed greater migration ability and expressed higher level of multiple
chemokines. Furthermore, we found that the level of HIF-1α, a direct target of miR-155, was increased in miR-155 deficient MDSCs, and that the increased HIF-1α upregulated CXCL1, CXCL3 and CXCL8 expression in MDSCs, contributing to the enhanced recruitment of miR-155(-/-) MDSCs to the
tumors. Moreover, miR-155(-/-) MDSCs showed enhanced immunosuppressive and pro-angiogenic capacities. Taken together, our study, for the first time, demonstrated that miR-155 deficiency promoted solid
tumor growth through increasing the recruitment of MDSCs to tumor microenvironment and enhancing the
tumor-promoting functions of the recruited MDSCs. Thus, upregulating miR-155 expression in MDSCs may be developed as a therapeutic approach to halt
tumor development.